BridgeMD
New treatment option for Esophageal Cancer
Official title Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
ClinicalTrials.gov ID: NCT06421376
What this study is testing
What is Cardonilizumab?
Cardonilizumab is an investigational medicine, being studied as a potential treatment for esophageal cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Although unprecedented advances have been made in the field of esophageal cancer in recent decades, the prognosis for patients with locally advanced esophageal squamous cell carcinoma (ESCC) remains extremely poor, accounting for 30-40% of overall survival at 5 year. In recent years, multimodal treatments have proven to be an appropriate therapeutic approach for locally advanced ESCC.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- 18-80 years old；
- Eligible patients were histologically confirmed esophageal squamous cell carcinoma;
- Eligible patients were proven locally advanced ESCC (cT1-2N1-3M0-1, cT3/T4N0-3M0-1, M1 was limited to supraclavicular lymph node metastasis）diagnosed...
- ECOG PS score: 0\~1；
- Main organs and bone marrow function are normal: routine blood tests: hemoglobin (Hb) ≥100g/L ; absolute neutrophil count (NEUT)≥1.5×109/L; platelets...
You likely can't join if
- Those combined with other primary malignant tumors other than esophageal cancer (except cured basal cell carcinoma of the skin and carcinoma in situ...
- patients who had previously received other treatments
- At the time of diagnosis, there were distant and hematogenous metastases beyond the supraclavicular lymph node region, including retroperitoneal...
- Those who already have esophageal perforation or are at high risk of esophageal perforation
- Patients whose tumors invade close to large blood vessels and are at risk of bleeding in the
- there are active infections, such as active tuberculosis and hepatitis
See the full eligibility criteria
- 18-80 years old；
- Eligible patients were histologically confirmed esophageal squamous cell carcinoma;
- Eligible patients were proven locally advanced ESCC (cT1-2N1-3M0-1, cT3/T4N0-3M0-1, M1 was limited to supraclavicular lymph node metastasis）diagnosed by computed tomography [CT] and/or endoscopic ultrasonography [EUS]...
- ECOG PS score: 0\~1；
- Main organs and bone marrow function are normal: routine blood tests: hemoglobin (Hb) ≥100g/L ; absolute neutrophil count (NEUT)≥1.5×109/L; platelets (PLT) ≥100×109/L; white blood cell (WBC)≥3.5×109/L,biochemical...
- Those combined with other primary malignant tumors other than esophageal cancer (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
- patients who had previously received other treatments
- At the time of diagnosis, there were distant and hematogenous metastases beyond the supraclavicular lymph node region, including retroperitoneal multiple lymph node metastasis, bone metastasis, brain metastasis, lung...
- Those who already have esophageal perforation or are at high risk of esophageal perforation
- Patients whose tumors invade close to large blood vessels and are at risk of bleeding in the
- there are active infections, such as active tuberculosis and hepatitis
- There are contraindications to immunotherapy.
- Pregnant or lactating women and women of childbearing age do not take reliable contraceptive measures
- Combined with serious cardiovascular diseases, such as uncontrolled heart failure, coronary heart disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or a history of myocardial infarction within...
- Violation of inclusion and exclusion criteria, or other reasons that the researcher believes cannot continue the study of drug treatment.
The study team makes the final eligibility decision.
Where it's taking place
- Anyang, Henan, China
- Xinxiang, Henan, China
- Beijing, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Anyang, Henan, China; Xinxiang, Henan, China; Beijing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.